![]() |
Name |
penicillidione A
|
Molecular Formula | C18H19NO5 | |
IUPAC Name* |
4-[(2-ethyl-5-hydroxy-3,5-dimethyl-4,6-dioxocyclohex-2-en-1-ylidene)methylamino]benzoicacid
|
|
SMILES |
CCC1=C(C)C(=O)C(C)(O)C(=O)C1=CNc1ccc(C(=O)O)cc1
|
|
InChI |
InChI=1S/C18H19NO5/c1-4-13-10(2)15(20)18(3,24)16(21)14(13)9-19-12-7-5-11(6-8-12)17(22)23/h5-9,19,24H,4H2,1-3H3,(H,22,23)/b14-9-/t18-/m1/s1
|
|
InChIKey |
AAMFCJMUKKFZCK-GIIHOQTISA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 329.35 | ALogp: | 2.3 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 103.7 | Aromatic Rings: | 2 |
Heavy Atoms: | 24 | QED Weighted: | 0.579 |
Caco-2 Permeability: | -5.169 | MDCK Permeability: | 0.00001350 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.983 |
Human Intestinal Absorption (HIA): | 0.043 | 20% Bioavailability (F20%): | 0.866 |
30% Bioavailability (F30%): | 0.077 |
Blood-Brain-Barrier Penetration (BBB): | 0.455 | Plasma Protein Binding (PPB): | 72.62% |
Volume Distribution (VD): | 0.408 | Fu: | 18.83% |
CYP1A2-inhibitor: | 0.029 | CYP1A2-substrate: | 0.268 |
CYP2C19-inhibitor: | 0.03 | CYP2C19-substrate: | 0.065 |
CYP2C9-inhibitor: | 0.039 | CYP2C9-substrate: | 0.12 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.079 |
CYP3A4-inhibitor: | 0.162 | CYP3A4-substrate: | 0.262 |
Clearance (CL): | 1.321 | Half-life (T1/2): | 0.626 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.077 |
Drug-inuced Liver Injury (DILI): | 0.987 | AMES Toxicity: | 0.416 |
Rat Oral Acute Toxicity: | 0.876 | Maximum Recommended Daily Dose: | 0.012 |
Skin Sensitization: | 0.194 | Carcinogencity: | 0.771 |
Eye Corrosion: | 0.149 | Eye Irritation: | 0.132 |
Respiratory Toxicity: | 0.982 |